Third Harmonic Bio, Inc. (THRD) Market Cap
Third Harmonic Bio, Inc. has a market capitalization of $242.8M.
Financials based on reported quarter end 2025-03-31
Price: $5.38
▼ -0.01 (-0.09%)
Market Cap: 242.79M
NASDAQ · time unavailable
CEO: Natalie C. Holles
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2022-09-14
Website: https://www.thirdharmonicbio.com
Third Harmonic Bio, Inc. (THRD) - Company Information
Market Cap: 242.79M · Sector: Healthcare
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Analyst Sentiment
Based on 5 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 3 sources)
Consensus Price Target
Low
$4
Median
$19
High
$23
Average
$16
Potential Upside: 200.2%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"THRD currently reports minimal revenue at $0, indicating it is in a pre-revenue state. For the fiscal quarter ending March 31, 2025, the company posted a net income loss of $15.83M and an operating cash flow deficit of $13.48M. With total assets of $279.84M and total liabilities of only $7.22M, THRD has a strong balance sheet with positive equity of $272.62M and net debt of -$268.61M, indicating significant cash reserves. However, negative earnings and cash flow raise concerns regarding profitability and operational efficiency. The latest dividends were paid in 2014, and there have been no distributions since, further pointing to financial challenges. Given these factors, the company is seen as a high-risk investment, especially without a clear path to revenue generation. Valuation metrics do not apply here owing to no actual market price or performance data available."
Revenue Growth
Pre-revenue status with no growth.
Profitability
Negative net income and operating loss.
Cash Flow Quality
Negative operating cash flow and free cash flow.
Leverage & Balance Sheet
Strong balance sheet with substantial equity and negative net debt.
Shareholder Returns
No dividends paid since 2014.
Analyst Sentiment & Valuation
No market price or recent performance data to support valuation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.